KZIA 6-K
Kazia Therapeutics Ltd (KZIA)
6-K
2025-06-10
For: 2024-12-31
View Original
Added on
April 06, 2026
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13a-16
OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of , 2025
Commission File Number
000-29962
(Translation of registrant’s name into English)
Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form
20-F
or Form 40-F.
Form
20-F ☒
Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation S-T
Rule 101(b)(1): ☐ Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation S-T
Rule 101(b)(7): ☐ INFORMATION CONTAINED IN THIS FORM
6-K
REPORT On June 9, 2025, Kazia Therapeutics Limited (the “Company”) reported its unaudited half-year results for the six months ended December 31, 2024, a copy of which is attached to this Form
6-K
as Exhibit 99.1. The Company hereby incorporates by reference the information contained herein into the Company’s registration statements on Form
F-3
(File No. 333-276091
and 333-281937).
EXHIBIT LIST
| Exhibit |
Description | |
| 99.1 | Half-year report for the six months ended December 31, 2024 | |
| 101.INS | XBRL Instance Document | |
| 101.SCH | XBRL Taxonomy Extension Schema Document | |
| 101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document | |
| 101.DEF | XBRL Taxonomy Extension Definition Linkbase Document | |
| 101.LAB | XBRL Taxonomy Extension Label Linkbase Document | |
| 101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Kazia Therapeutics Limited |
/s/ John Friend |
| John Friend |
| Chief Executive Officer |
| Date: 10 June 2025 |